[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636860":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":34,"responsibleParty":157,"collaborators":19,"id":159,"slug":160,"hasResults":161,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":19,"eligibilityCriteria":165,"healthyVolunteers":161,"sex":166,"minAge":167,"maxAge":168,"enrollmentInfo":169,"targetDuration":19,"studyType":172,"phases":173,"briefSummary":175,"conditions":176,"keywords":19,"overallStatus":54,"whyStopped":19,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"LY4256984","EXPERIMENTAL","LY4256984 administered intrathecally (IT)",[13],"Drug: LY4256984",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Administered IT",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","LillyTrials@Lilly.com",{"name":31,"role":27,"phone":32,"phoneExt":19,"email":33},"Physicians interested in becoming principal investigators please contact","3176154559","clinical_inquiry_hub@lilly.com",[35,52,67,79,93,105,117,131,145],{"facility":36,"status":37,"city":38,"state":19,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"UZ Leuven","NOT_YET_RECRUITING","Leuven","3000","Belgium","BE",{"type":43,"coordinates":44},"Point",[45,46],4.70093,50.87959,{"lat":46,"lon":45},[49],{"name":50,"role":51,"phone":19,"phoneExt":19,"email":19},"Philip Van Damme","PRINCIPAL_INVESTIGATOR",{"facility":53,"status":54,"city":55,"state":19,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"McGill University Health Centre","RECRUITING","Montreal","H4A 3J1","Canada","CA",{"type":43,"coordinates":60},[61,62],-73.58781,45.50884,{"lat":62,"lon":61},[65],{"name":66,"role":51,"phone":19,"phoneExt":19,"email":19},"Angela Genge",{"facility":68,"status":37,"city":69,"state":19,"zip":70,"country":57,"countryCode":58,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Sunnybrook Research Institute","Toronto","M4N 3M5",{"type":43,"coordinates":72},[73,74],-79.39864,43.70643,{"lat":74,"lon":73},[77],{"name":78,"role":51,"phone":19,"phoneExt":19,"email":19},"Agessandro Abrahao",{"facility":80,"status":37,"city":81,"state":19,"zip":82,"country":83,"countryCode":84,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Universitätsklinikum Schleswig-Holstein","Lübeck","23538","Germany","DE",{"type":43,"coordinates":86},[87,88],10.68729,53.86893,{"lat":88,"lon":87},[91],{"name":92,"role":51,"phone":19,"phoneExt":19,"email":19},"Julian Grosskreutz",{"facility":94,"status":37,"city":95,"state":19,"zip":96,"country":83,"countryCode":84,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Universitätsmedizin Rostock","Rostock","18147",{"type":43,"coordinates":98},[99,100],12.14049,54.0887,{"lat":100,"lon":99},[103],{"name":104,"role":51,"phone":19,"phoneExt":19,"email":19},"Andreas Hermann",{"facility":106,"status":37,"city":107,"state":19,"zip":108,"country":83,"countryCode":84,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"Universitaetsklinikum Ulm","Ulm","89081",{"type":43,"coordinates":110},[111,112],9.99155,48.39841,{"lat":112,"lon":111},[115],{"name":116,"role":51,"phone":19,"phoneExt":19,"email":19},"Jochen Weishaupt",{"facility":118,"status":37,"city":119,"state":19,"zip":120,"country":121,"countryCode":122,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Universitair Medisch Centrum Utrecht","Utrecht","3584 CX","Netherlands","NL",{"type":43,"coordinates":124},[125,126],5.12222,52.09083,{"lat":126,"lon":125},[129],{"name":130,"role":51,"phone":19,"phoneExt":19,"email":19},"Leonard H. Berg",{"facility":132,"status":37,"city":133,"state":19,"zip":134,"country":135,"countryCode":136,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"Hospital Universitari de Bellvitge","L'Hospitalet de Llobregat","08907","Spain","ES",{"type":43,"coordinates":138},[139,140],2.10028,41.35967,{"lat":140,"lon":139},[143],{"name":144,"role":51,"phone":19,"phoneExt":19,"email":19},"MONICA POVEDANO PANADES",{"facility":146,"status":37,"city":147,"state":19,"zip":148,"country":135,"countryCode":136,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"Hospital Universitari i Politecnic La Fe","Valencia","46026",{"type":43,"coordinates":150},[151,152],-0.37966,39.47391,{"lat":152,"lon":151},[155],{"name":156,"role":51,"phone":19,"phoneExt":19,"email":19},"Juan Vazquez-Costa",{"type":158,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100636860","phase-1-a-substudy-of-ly4256984-in-participants-with-sporadic-amyotrophic-lateral-sclerosis-100636860",false,"NCT07571174","A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis","A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Long-Term Extension of Study J6I-MC-OWAA","Participants must meet eligibility criteria in the \\[L0U-MC-OLMP\\] screening protocol before entry into the treatment study.\n\nInclusion Criteria:\n\n* Have completed the main treatment period\u002Fphase as well as any off-treatment period\u002Fphase of Study OWAA, the parent study for this ISA.\n\nExclusion Criteria:\n\n* The participant has conditions that preclude a lumbar puncture (LP), such as:\n\n  * A history of clinically significant back pain, back pathology, and\u002For back injury (for example, degenerative disease, spinal deformity, or spinal surgery) that may predispose to complications or technical difficulty with LP.\n  * Allergy to local anesthetics, such as lidocaine or its derivatives.\n  * A local infection at the intended site of the LP.\n  * Less than 100 giga per liter \\[(\\\u003C100 GI\u002FL) is equivalent to 100,000 per cubic millimeter (100,000\u002Fmm³)\\] platelets or clinically significant coagulation abnormality or significant active bleeding, or\n  * Currently receiving treatment with an anticoagulant, antiplatelet agent, or other drug that affects coagulation or platelet function. Low dose (according to local medical guidelines) aspirin is permitted.","ALL","18 Years","80 Years",{"count":170,"type":171},32,"ESTIMATED","INTERVENTIONAL",[174],"PHASE1","The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6I-MC-OWAA (NCT07100119) and is part of the OLMP (NCT07571200) master protocol that will last approximately 96 weeks.",[177],"Amyotrophic Lateral Sclerosis","2026-06-19",{"date":180,"type":181},"2026-06-24","ACTUAL",{"date":183,"type":181},"2026-05-14",{"date":185,"type":171},"2029-06",{"name":5,"class":6},9]